TRAF3 and Miyoshi myopathy: The frequent association of TRAF3 loss in MM and BCL, as well as mechanisms of post-translational loss of TRAF3 that may impact an additional group of B cell malignancies, suggest that this loss predisposes B cells to transformation, oncogenesis, and possibly resistance to conventional chemotherapy, because TRAF3 deficiency selectively enhances B cell survival without altering proliferation4.